{"id":2354,"date":"2010-12-07T10:42:30","date_gmt":"2010-12-07T15:42:30","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=2354"},"modified":"2010-12-07T10:42:30","modified_gmt":"2010-12-07T15:42:30","slug":"trial-shows-results-for-multiple-myeloma-therapy","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=2354","title":{"rendered":"Trial Shows Results for Multiple Myeloma Therapy"},"content":{"rendered":"<figure id=\"attachment_2356\" aria-describedby=\"caption-attachment-2356\" style=\"width: 220px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/12\/MyelomaCells_NIH.gif\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-2356\" title=\"MyelomaCells_NIH\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/12\/MyelomaCells_NIH.gif\" alt=\"Myeloma cells (NIH)\" width=\"220\" height=\"220\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/12\/MyelomaCells_NIH.gif 220w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/12\/MyelomaCells_NIH-150x150.gif 150w\" sizes=\"auto, (max-width: 220px) 100vw, 220px\" \/><\/a><figcaption id=\"caption-attachment-2356\" class=\"wp-caption-text\">Myeloma cells (NIH)<\/figcaption><\/figure>\n<p>Onyx Pharmaceuticals Inc. in Emeryville, California says that a <a href=\"http:\/\/www.onyx-pharm.com\/view.cfm\/711\/Onyx-Pharmaceuticals-Announces-Positive-Complete-Results-from-Carfilzomib-Phase-2b-Study\">clinical trial<\/a> of its drug carfilzomib showed a sizable percentage of patients with multiple myeloma responded to treatment and for a relatively long period of time. <a href=\"http:\/\/www.nlm.nih.gov\/medlineplus\/multiplemyeloma.html\">Multiple myeloma<\/a> is a cancer of the plasma cells in bone marrow.<\/p>\n<p>Carfilzomib is a <a href=\"http:\/\/www.cancer.gov\/dictionary\/?CdrID=393541\">proteasome inhibitor<\/a> that blocks the action of proteasomes, which are large protein complexes that help destroy other cellular proteins when they are no longer needed. The <a href=\"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00511238?term=onyx&amp;rank=6\">phase 2 trial<\/a> involved 266 patients with relapsed or refractory multiple myeloma, who had received a median of five previous lines of therapy.<\/p>\n<p>The company says about a quarter (24.1%) of the subjects had at least a partial response to the carfilzomib treatment, with a median duration of response of 8.3 months. The clinical benefit rate of the drug &#8212; defined as having at least a minimal response &#8212; was about a third (34%) of the subjects. The median overall survival was 15.5 months.<\/p>\n<p>Onyx says no new or unexpected toxicities were found in the overall study population. The most common adverse effects were low blood platelet count and anemia.<\/p>\n<p>The data are expected to be presented 7 December at the American Society of Hematology annual meeting in Orlando, Florida.<\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Onyx Pharmaceuticals Inc. in Emeryville, California says that a clinical trial of its drug carfilzomib showed a sizable percentage of patients with multiple myeloma responded to treatment and for a relatively long period of time. Multiple myeloma is a cancer of the plasma cells in bone marrow. Carfilzomib is a proteasome inhibitor that blocks the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[31,51,28,27],"class_list":["post-2354","post","type-post","status-publish","format-standard","hentry","category-products","tag-biomedical","tag-cancer","tag-clinical-trials","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2354"}],"version-history":[{"count":4,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2354\/revisions"}],"predecessor-version":[{"id":2359,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2354\/revisions\/2359"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}